Novavax (NVAX) ended the recent trading session at $10, demonstrating a -1.19% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.92%. At ...

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.

B.Riley Financial analyst Mayank Mamtani has maintained their bullish stance on CYTK stock, giving a Buy rating on October 17. Mayank Mamtani ...

Mid- to late October is the best time to get flu and COVID vaccines, so they will be effective during November and December holiday gatherings.

The UK Government has recommended offering a COVID-19 booster vaccination in autumn, 2024, to individuals at high risk of ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.14 which represents a decrease of $-0.04 or -0.39% from the prior close of $10.18. The stock opened at $10.1 and touched a low ...

Oct. 15, 2024 — Experts have announced that the Sun has reached its solar maximum period, which could continue for the next year. Scientists will not be able to determine the exact peak of this ...

However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...